TNF-α blocking therapy in chronic inflammatory bowel disease;TNF-α-blokkoló kezelés krónikus, ismeretlen eredetu gyulladásos bélbetegségekben

Orvosi Hetilap

Volumn 150, Issue 38, 2009, Pages 1773-1779

  Molnár, Tamás ^a,b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b NONE   (Hungary)

Author keywords

Adalimumab; Crohn's disease; IBD; Infliximab; TNF ; Ulcerative colitis

Indexed keywords

ADALIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

CROHN DISEASE; DISEASE SEVERITY; DRUG EFFICACY; ENTERITIS; HUMAN; IMMUNOTHERAPY; REMISSION; REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 70349215021     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2009.28689     Document Type: Review

References (23)

1. Laroux, F. S., Pavlick, K. P., Wolf, R. E. és mtsai: Dysregulation of intestinal mucosal immunity: implications in inflammatory bowel disease. News Physiol. Sci., 2001, 16, 272-277.
2. Podolsky, D. K.: Inflammatory bowel disease. N. Eng. J. Med., 2002, 347, 417-429.
3. Sartor, R. B.: Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology, 1994, 106, 533-539.
4. Lukacs, N. W., Chensue, S. W., Strieter, R. M. és mtsai: Inflammatory granuloma formation is mediated by TNF-alpha inducible intercellular adhesion molecule-1. J. Immunol., 1994, 152, 5883-5889.
5. Knight, D. M., Trinh, H., Le, J. és mtsai: Construction and initial characterization of mouse human chimeric anti-TNF antibody. Mol. Immunol., 1993, 30, 1443-1453.
6. Chaudhary, R., Ghosh, S.: Prediction of response to infliximab in Crohn's disease. Digestive and Liver Disease, 2005, 37, 559-563.
7. Parsi, M. A., Achkar, J., Richardson, S. és mtsai: Predictors of response to inflximab in patients with Crohn's disease. Gastroenterology, 2002, 123, 707-713.
8. Hommes, D. W., Oldenburg, B., van Bodegraven, A. A. és mtsai: Guidelines for treatment with infliximab for Crohn's disease. The Netherlands Journal of Medicine, 2006, 64, 219-229. (Pubitemid 44203651)
9. Rutgeerts, P., van Assche, G., Vermeire, S.: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology, 2004, 126, 1593-1610. (Pubitemid 38649876)
10. Vermeire, S., Noman, M., van Assche, G. és mtsai: Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut, 2007, 56, 1181-1183.
11. Targan, S. R., Hanauer, S. B., Deventer, S. B. és mtsai: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N. Engl. J. Med., 1997, 337, 1029-1035.
12. Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R. és mtsai: Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet, 2002, 359, 1541-1549.
13. Present, D. H., Rutgeerts, P., Targan, S. és mtsai: Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med., 1999, 340, 1398-1405.
14. Sands, B. E., Anderson, F. H., Bernstein, C. N. és mtsai: Infliximab maintenance therapy forflstulizing Crohn's disease. N. Eng. J. Med., 2004, 350, 934-936.
15. Molnár, T., Farkas, K., Miheller, P. és mtsai: Medium term efficacy of infliximab induction therapy without retreatment in patients with Crohn's disease. Journal of Crohn's and Colitis, 2008, 2, 322-326.
16. Hyams, J., Crandall, W., Kugathasan, S. és mtsai: Induction and maintenance of in fliximab therapy for the treatment of moderate to severe Crohn's disease in children. Gastroenterology, 2007, 132, 863-873.
17. Thayu, M., Leonard, M. B., Hyams, J. és mtsai: Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin. Gastroenterol. Hepatol., 2008, 6, 1378-1384.
18. Rutgeerts, P., Vermeire, S., van Assche, G.: Biological therapies for in flammatory bowel diseases. Gastroenterology, 2009, 136, 1182-1197.
19. Feagan, B., McDonald, J. W. D., Panaccione, R. és mtsai: A randomized, placebo-controlled study to evaluate the efficacy of infliximab in combination with methotrexate for the long-term treatment of Crohn's disease. Gastroenterology 2008, 135, 294 (Abstract).
20. Sandborn, W. J., Rutgeerts, P., Reinisch, W. és mtsai: SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Am. J. Gastroenterology, 2008, Abstract ACG.
21. Reguiero, M., Siemanowski, B., Kip, K. E. és mtsai: In fliximab dose intensification in Crohn's disease. Inflamm. Bowel Dis., 2007, 13, 1093-1099.
22. Chey, W. Y.: Infliximab for patients with refractory ulcerative colitis. Inflamm. Bowel Dis., 2001, 7, S30-S33.
23. Sands, B. E., Tremaine, W. J., Sandborn, W. J. és mtsai: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm. Bowel Dis., 2001, 7, 83-88.